soul trial oral semaglutide cardiovascular outcomes results 2025 nejm 2024 Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Oral Semaglutide and Cardiovascular Outcomes

Metformin remains the first-line pharmacological treatment for glycaemic control in type 2 diabetes, following dietary and lifestyle advice

GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)are used to manage type 2 diabetes and obesity in the UK

bit.ly/47IaqNS?utm_medium=social&utm_source=facebook_WWLTV #CancerResearch #GLP1 #Obesity #Cancer #Health #HealthNews #MedicalResearch | WWLTV

M., Escamilla-Powers, J

With proper training and preparation, you can be at the forefront of this transformative approach to addressing childhood obesity, making a lasting impact in the lives of children and their families